NEW YORK, NY / ACCESSWIRE / July 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CCIV Shareholders Click Here: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18117&wire=1
FREQ Shareholders Click Here: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=18117&wire=1
RLX Shareholders Click Here: https://www.zlk.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=18117&wire=1
* ADDITIONAL INFORMATION BELOW *
Churchill Capital Corp IV (NYSE:CCIV)
CCIV Lawsuit on behalf of: investors who purchased January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline: August 30, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=18117&wire=1
According to the filed complaint, during the class period, Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
FREQ Lawsuit on behalf of: investors who purchased November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=18117&wire=1
According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=18117&wire=1
According to the filed complaint, the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP